ArticleIn silico pharmacology2026
Chinese herbal Formula Q attenuates letrozole-induced polycystic ovary syndrome through modulating multiple metabolic processes in female adult rats.
Article in In silico pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is driven by multiple factors, but detailed mechanisms in the setting of PCOS remains unclear. Our study is to comprehensively clarify the potentially molecular mechanisms of effect Formulae Q (Traditional Chinese Medicine) on PCOS. A model of PCOS-liked rats induced by letrozole (1 mg/kg/d) for 21days was performed. Formulae Q (20 g/kg/d) was orally gavaged twice daily to rats as a pretreatment, and metformin (100 mg/kg/d) was orally gavaged daily as a positive control. HE stains were performed to assess pathological changes of the ovaries, and the number of corpuses luteum and cysts were assessed. Biochemistry test was used to measure testosterone, E2, FSH, LH, AMH and LH/FSH in serum. All the target proteins were identified by proteomics and bioinformatics analyses, and then verified by qPCR. The core components of Formulae Q identified by UPLC-MS/MS were subjected to molecular docking with target proteins.As a result, Formulae Q had a obviously protective-effect against PCOS by reversing alters of hormone levels in serum and pathology in ovary tissues. Proteomics data are available via ProteomeXchange with identifier PXD057910. Formula Q significantly inhibited Zp family related indexes (Zp2, Zp3 and Zp4). Furthermore, pharmachologic effectts of Formula Q were closely related to steroidogenesis metabolism (Cyp17a1, Ass1 and Apoc1), synthesis and metabolism processes (Cbr1l1, Fdx1 and Dpep1), signaling and cellular processes (Calb2, Dcn and Reep6), and the other biological processes (Fdx1, Hdgfl3, Lgals1 and Tagin). The Cbr1l1 protein showed strong binding affinity with the four core components of Formulae Q.These findings suggest that Formulae Q may hold promise as a potential candidate for PCOS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.